Table 1 A20 abnormalities in lymphocytic malignancy
From: The role of A20 in the pathogenesis of lymphocytic malignancy
Diagnosis | Number of cases | Deletion (%) | Mutation (%) | Location | Reference |
|---|---|---|---|---|---|
cHL | 36 | 44 | OUT, ZF domain | [47] | |
EBV+ | 16 | 12.5 | - | ||
EBV- | 20 | 70 | - | ||
NSHL | 15 | 33.3 | Exons 3, 4, and 7 | [28] | |
other HL | 27 | 26 | [48] | ||
MZL | 32 | 2 | 19 | Exons 3, 6, and 7 | [46] |
EMZL | 11 | 18 | Exons 3 and 7 | ||
NMZL | 9 | 33 | Exons 3, 6, and 7 | ||
sMZL | 12 | 8 | Exon 6 | ||
sMZL | 46 | 6.5 | 6.5 | - | [49] |
MALTL | 30 | 6 | 17.6 | C1777T; C811T; G460T/△CT1877-8 | [50] |
87 | 21.8 | Exons 3, 5, 6, 7, and 9 | [28] | ||
64 | 17.2 | - | [45] | ||
9 | 11 | Exon 3 | [1] | ||
DLBCL | 64 | 7.8 | 2 | [28] | |
102 | 38 | - | [45] | ||
GCB type | 18 | 22.2 | - | [45] | |
ABC type | 28 | 50 | - | [45] | |
GCB type | 44 | 2.3 | - | [33] | |
ABC type | 37 | 32 | 23 | - | [33] |
non-GC/NC-DCBCL | 20 | 34 | 22 | - | [33] |
MCL | 35 | 0 | - | [28] | |
29 | 31 | - | [45] | ||
FL | 52 | 1.9 | - | [28] | |
23 | 26 | - | [45] | ||
PMBL | 14 | 36 | - | [47] | |
Burkitt L | 19 | 10.5 | - | [45] | |
NK L | 27 | 18.5 | - | [45] | |
ATLL | 68 | 10.3 | - | [45] | |
PTCL-u | 51 | 9.8 | - | [45] | |
CTCL | 13 | 46 | - | [51] | |
ARL | 33/19 | 18 | 16 | - | [52] |
PCNSL | 32 | 3 | - | [53] | |
spinal cord DLBCL | 10 | 10 | - | [53] | |
CLL | 48 | 27 | 2 | - | |
55 | 0 |